239 results on '"Palloni Andrea"'
Search Results
2. Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma
3. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
4. Can repeated surgical resection offer a chance of cure for recurrent cholangiocarcinoma?
5. Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
6. A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index
7. Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance.
8. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
9. The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center
10. Treatment Sequencing and Independent Outcomes of First- and Second-Line Chemotherapy in a Retrospective Series of Patients with Biliary Tract Cancer.
11. Chemoradiation of locally advanced biliary cancer: A PRISMA‐compliant systematic review.
12. THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab
13. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC
14. Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree
15. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
16. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
17. Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster
18. Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
19. Neoadjuvant chemotherapy alone or combined with trans-arterial therapies for downstaging unresectable intrahepatic cholangiocarcinoma to surgical resection: a narrative review
20. Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma
21. An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone
22. Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
23. The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
24. Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
25. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
26. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
27. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
28. Advances in novel systemic therapies for advanced hepatocellular carcinoma
29. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
30. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
31. Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention
32. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
33. Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy
34. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study
35. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
36. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
37. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis
38. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy
39. Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
40. A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index
41. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
42. Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.
43. Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.
44. Nivolumab: an investigational agent for the treatment of biliary tract cancer
45. Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
46. Experimental HER2- targeted therapies for biliary tract cancer
47. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
48. Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
49. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
50. Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.